ArticleCirculation research2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit
Article in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02501811 (A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF
Who cites it
55 citing papers in PubMed.
- Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c-Kit-Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT-HF Clinical Trial.Journal of the American Heart Association · 2026Trial
- A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.European journal of heart failure · 2021Trial
- Human myocardial-derived highly proliferative cells improve cardiac remodeling after myocardial infarction in mice.The Journal of pharmacology and experimental therapeutics · 2025Article
- Stem Cell Therapy Approaches for Ischemia: Assessing Current Innovations and Future Directions.International journal of molecular sciences · 2025Review
- Cross-sectional evaluation of the metabolic vulnerability index in heart failure populations.BMC cardiovascular disorders · 2025Article
- Efficacy of mesenchymal stem cells in treating tracheoesophageal fistula via the TLR4/NF-κb pathway in beagle macrophages.Heliyon · 2024Article
- Large-scale bioreactor production of extracellular vesicles from mesenchymal stromal cells for treatment of acute radiation syndrome.Stem cell research & therapy · 2024Article
- Mesenchymal stem cell-derived exosomes: a promising alternative in the therapy of preeclampsia.Stem cell research & therapy · 2024Review
- C-kitHeliyon · 2023Article
- Article
- Regeneration of the heart: from molecular mechanisms to clinical therapeutics.Military Medical Research · 2023Review
- Knockdown of deleterious miRNA in progenitor cell-derived small extracellular vesicles enhances tissue repair in myocardial infarction.Science advances · 2023Article
- Paracrine effects of mir-210-3p on angiogenesis in hypoxia-treated c-kit-positive cardiac cells.Annals of medicine · 2023Article
- Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study).Pediatric cardiology · 2022Article
- Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.Cardiovascular research · 2022Review
- Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction.Stem cells translational medicine · 2022Article
- Cardiac stem cells: Current knowledge and future prospects.World journal of stem cells · 2022Review
- Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?Stem cell reviews and reports · 2022Review
- From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting.Frontiers in cell and developmental biology · 2022Review
- Effect and application of cryopreserved three-dimensional microcardiac spheroids in myocardial infarction therapy.Clinical and translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
rationaleAutologous bone marrow mesenchymal stem cells (MSCs) and c-kit
objectiveCONCERT-HF (Combination of Mesenchymal and c-kit METHODS AND
resultsUsing a randomized, double-blinded, placebo-controlled, multicenter, multitreatment, and adaptive design, CONCERT-HF examines whether administration of MSCs alone, CPCs alone, or MSCs+CPCs in this population alleviates left ventricular remodeling and dysfunction, reduces scar size, improves quality of life, or augments functional capacity. The 4-arm design enables comparisons of MSCs alone with CPCs alone and with their combination. CONCERT-HF consists of 162 patients, 18 in a safety lead-in phase (stage 1) and 144 in the main trial (stage 2). Stage 1 is complete, and stage 2 is currently randomizing patients from 7 centers across the United States.
conclusionsCONCERT-HF will provide important insights into the potential therapeutic utility of MSCs and CPCs, given alone and in combination, for patients with HF secondary to ischemic cardiomyopathy. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT02501811.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.